Medcura Expands Board of Directors with Domain and Commercial Strategy Expert

Medcura Inc. a privately held, clinical-stage medical device company, announces the expansion of its Board of Directors to include industry veteran Jim Buck.Medcura’s proven platform and continued success is attracting key talent. Chosen for his ability to guide the Company from an early-stage developer of cleared medical devices to becoming a global hemostatic brand, Jim brings highly relevant skillsets, experiences and relationships from over 25 years of working in the medical device field, particularly in the development and commercialization of hemostatic product lines. .“We’re fortunate to have talent the likes of Jim joining our Board, bringing with him experience in developing and commercializing hemostatic devices,” said Alexander K. Arrow, MD, CFA, Director of Medcura. “I look forward to serving with him. Currently the President and CEO of Mardil Medical, Jim has a solid history of leadership within successful medical device developers, including St. Jude Medical, InnerPulse and SetPoint Medical. This, coupled with his experience in developing surgical hemostats at Johnson & Johnson’s Closure Medical, provides a unique foundation for guiding strategy at Medcura as we expand the use of our platform from treating external to internal hemostatic clinical needs.”You can learn more about Jim’s background by visiting https://medcurainc.com/team/“I’m enthusiastic about joining the Medcura team,” said Buck. “The foundation that exits already at Medcura in technology, intellectual property and regulatory success are the core assets I’ve watched grow into other similar, now successful, medical device enterprises. Having watched the use of surgical hemostats expand over the past 20 years and with the marked increase in blood thinner prescriptions over the past few years, Medcura has the opportunity to be “the” platform for bleeding control in the operating room and in the backyard.”